18 Dec 2020 07:00
Board Appointment
Tony Bourne to join as Independent Non-Executive Director
Oxford, U.K. 18 December 2020: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company"), the Clinical AI company, today announced the appointment of Tony Bourne to the Board as Independent Non-Executive Director with effect from 31 January 2021. He will also serve as Chair of the Remuneration Committee.
Tony Bourne has considerable experience and knowledge of the healthcare and financial services industries. He was Chief Executive of the British Medical Association between 2005 and 2013. Prior to this he was in investment banking for over 25 years, including as a partner of independent corporate finance advisory firm Hawkpoint, as global head of the equities division and a member of the managing board of Paribas and held senior roles at Merrill Lynch, European Banking Company and James Capel & Co.
Tony currently serves as Chair of CW+ (the official charity of Chelsea and Westminster Hospital NHS Foundation Trust), and is additionally an Independent Non-Executive Director to the Boards of Barchester Healthcare, Spire Healthcare Group PLC and Totally PLC.
Sir Bruce Keogh, Non-Executive Chairman of Sensyne, said
"I'm delighted to welcome Tony to the Board at a time of tremendous progress for Sensyne. His track record and deep expertise in the healthcare space, as well as a distinguished career in the financial services industry, will be invaluable to us as we embark on the next phase of our growth - building an innovative world class clinical data and artificial intelligence company."
The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:
Full name and age: Anthony (Tony) Rhys Bourne (age 67)
Current Directorships or Partnerships:
153 Holland Park Avenue RTM Company Limited
Barchester Healthcare Limited
Barchester Holdco (Jersey) Limited
Barchester Finco 2019 Limited
Barchester Hellens Limited
CWPlus
Grove Limited
Spire Healthcare Group plc
Totally plc
Directorships or Partnerships within the last five years
Bioquell Limited
CWHC Trading Limited
Remedium Partners Limited
Universal Drilling & Cutting Equipment Limited
Universal Engineering Holdings Limited
VirtualStock Holdings Limited
VirtualStock Limited
No further information in connection with his appointment is required to be disclosed under Schedule Two, paragraph (g) of the Aim Rules for Companies.
-ENDS-
For more information please contact:
Sensyne Health (www.sensynehealth.com) | +44 (0) 330 0581845 |
Lord (Paul) Drayson PhD FREng FMedSci, Chief Executive Officer | |
Michael Norris, Interim Chief Financial Officer | |
Peel Hunt LLP (Nominated Adviser and Joint Broker) |
+ 44 (0) 20 7418900 |
Dr Christopher Golden | |
James Steel | |
Oliver Jackson | |
Liberum (Joint Broker) | + 44 (0) 201002000 |
Bidhi Bhoma | |
Euan Brown | |
Consilium Strategic Communications | +44 (0) 7780600290 |
Mary-Jane Elliott | |
Sukaina Virji | |
Melissa Gardiner | |
sensynehealth@consilium-comms.com |
About Sensyne Health
Sensyne Health plc is a clinical AI company that works in partnership with global healthcare organisations to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
For more information, please visit: www.sensynehealth.com